LON:CREO Creo Medical Group (CREO) Share Price, News & Analysis GBX 11.92 -0.20 (-1.65%) As of 07:54 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesBuy This Stock About Creo Medical Group Stock (LON:CREO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Creo Medical Group alerts:Sign Up Key Stats Today's Range 11.75▼ 12.4450-Day Range 10.40▼ 14.2552-Week Range 9.52▼ 18.50Volume224,498 shsAverage Volume810,976 shsMarket Capitalization£49.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures. For more information, please refer to the website www.creomedical.com Read More Receive CREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Creo Medical Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CREO Stock News HeadlinesCreo Medical reports 50% revenue growth and cost reduction in FY25January 20, 2026 | ca.investing.comCreo Medical Announces Capital Markets Day for InvestorsOctober 27, 2025 | msn.comCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens with silver. But it is now possible thanks to a new ETF that delivers the best of worlds.May 14 at 1:00 AM | Investors Alley (Ad)Creo Medical hails US reimbursement milestone for Speedboat procedureMay 28, 2025 | lse.co.ukCreo Medical Group Full Year 2024 Earnings: Misses ExpectationsMay 20, 2025 | finance.yahoo.comCreo Medical has "positive outlook", despite widened 2024 lossMay 19, 2025 | lse.co.ukInsider Stock Buying Reaches UK£985.5k On Creo Medical GroupApril 4, 2025 | uk.finance.yahoo.comCreo Medical Updates Shareholder NotificationApril 1, 2025 | tipranks.comSee More Headlines CREO Stock Analysis - Frequently Asked Questions How have CREO shares performed this year? Creo Medical Group's stock was trading at GBX 10 at the beginning of the year. Since then, CREO shares have increased by 24.4% and is now trading at GBX 12.44. How were Creo Medical Group's earnings last quarter? Creo Medical Group PLC (LON:CREO) announced its quarterly earnings data on Monday, September, 22nd. The company reported $4.00 earnings per share (EPS) for the quarter. Creo Medical Group had a net margin of 768.18% and a trailing twelve-month return on equity of 32.72%. How do I buy shares of Creo Medical Group? Shares of CREO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Creo Medical Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Creo Medical Group investors own include Aviva (AV), IQE (IQE), Lloyds Banking Group (LLOY), Barclays (BARC), BP (BP), BT Group (BT.A) and Coats Group (COA). Company Calendar Last Earnings9/22/2025Today5/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:CREO CIKN/A Webcreomedical.com Phone+44-1291-606005FaxN/AEmployees279Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£25.04 million Net Margins768.18% Pretax MarginN/A Return on Equity32.72% Return on Assets-20.09% Debt Debt-to-Equity Ratio6.90 Current Ratio5.28 Quick Ratio2.19 Sales & Book Value Annual Sales£4.60 million Price / Sales10.69 Cash FlowGBX 4.90 per share Price / Cash Flow2.43 Book ValueGBX 13.11 per share Price / Book0.91Miscellaneous Outstanding Shares412,473,000Free FloatN/AMarket Cap£49.19 million OptionableNot Optionable Beta1.50 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:CREO) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersOne coin wired into Elon's visionThe Kevin Warsh Fed takeover is here. And he's brought a thesis with him that almost nobody is talking about. ...Crypto 101 Media | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creo Medical Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Creo Medical Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
